First site initiation in Austria

May 29, 2020/in News /by philiprye

The OligoGpivotalCF trial is about to start recruiting. On 6th May 2020 the first site was initiated in Wels, Austria and more site initiation visits are planned for the coming months. Pending the normalization of the Covid-19 pandemic, the trial will open for patients at several sites in Europe soon.

If you want to know more, visit www.OligoGpivotalCF.eu

About the project

OligoG-pivotal-CF is a multinational clinical project to test the orphan drug OligoG CF-5/20 (OligoG) in a pivotal phase 2b clinical trial for the treatment of cystic fibrosis (CF). The project is funded by the H2020-SC1-2017-Two-Stage-RTD, topic SC1-PM-08-2017, and represents a new therapy for the rare disease cystic fibrosis (CF). The study drug OligoG CF-5/20 (OligoG) has received an EU Orphan Drug Medicinal Product Designation in 2007 and an FDA Orphan Drug Designation February 2016, both for the treatment of cystic fibrosis.

First site initiation in Austria

First site initiation in Austria

About the project

Contact information

Funding